GLP-1 Drugs for Teens With Obesity: What the Trials Show

GLP-1 drugs can reduce weight and improve several metabolic risk markers in adolescents with obesity. That conclusion comes from pediatric randomized trials, not a guess based on adult results. But the evidence base remains small: five trials, 600 participants, varied drugs and protocols, and no published pediatric data on what happens after treatment stops.

The useful middle ground sits between panic and sales copy. Semaglutide and liraglutide have regulatory approval for adolescents aged 12 years and older who meet the relevant obesity criteria. They are legitimate medical treatments, not cosmetic shortcuts. They also raise questions that short trials cannot answer about years of use during growth, puberty, and bone development.

What the pediatric trials found

A 2026 systematic review and meta-analysis by Sukkar et al. pooled five randomized, placebo-controlled trials of GLP-1 receptor agonists in children and adolescents with obesity. The 600 participants received semaglutide, liraglutide, exenatide, or dulaglutide, depending on the trial; semaglutide was studied at 2.4 mg by weekly injection and liraglutide at doses up to 3.0 mg by daily injection.

Across those trials, GLP-1 treatment produced statistically significant average differences versus placebo of:

• 2.33 kg/m² lower BMI
• 6.69 kg lower body weight
• 4.53 cm smaller waist circumference
• 0.14 percentage points lower HbA1c
• 2.25 mmHg lower systolic blood pressure

These are group averages, not promises for an individual teenager. The meta-analysis found high heterogeneity for the anthropometric outcomes: results differed substantially across trials. Different agents, doses, treatment durations, and participant populations can all change the observed effect. The systolic-blood-pressure result showed less heterogeneity, but it remains a surrogate marker rather than evidence that the drugs prevent heart attacks or strokes in young people.

The pooled weight and waist results matter clinically because adolescent obesity often travels with insulin resistance, elevated blood pressure, abnormal lipids, and fatty liver disease. Still, a lower HbA1c or waist measurement does not by itself establish fewer future cardiovascular events. Adolescents almost never experience enough hard cardiovascular outcomes during trials to measure that question directly.

Semaglutide improved more than the scale reading

Weight loss is the main reason these medicines draw attention, but it is not the only measured outcome. A 2025 secondary analysis of the STEP TEENS trial by Arslanian et al. compared semaglutide 2.4 mg once weekly with placebo in adolescents with obesity. It reported improved insulin sensitivity and multiple cardiometabolic risk factors alongside weight reduction.

That finding supports the view that semaglutide's effects in adolescents extend beyond a simple reduction in calorie intake. It does not prove which biological pathway caused each improvement. GLP-1 drugs affect appetite, gastric emptying, pancreatic beta-cell function, and glucose metabolism, among other systems. The secondary analysis shows that the measured risk factors improved; it does not separate the direct drug effect from changes that followed weight loss, nor does it provide a mechanistic verdict.

The publication is also a secondary analysis, so it should not carry more weight than the underlying randomized trial's primary outcomes. The available abstract does not provide numerical effect estimates for each insulin-sensitivity or cardiometabolic endpoint. It is accurate to say the measures improved, but not to invent a percentage change or claim a specific degree of clinical benefit.

Side effects are common enough to affect treatment

In the pediatric meta-analysis, gastrointestinal adverse events, especially nausea and vomiting, occurred more often with GLP-1 drugs than with placebo. That fits the class's known effects on appetite and gastric emptying. The review described overall safety as comparable between treatment groups, but "comparable" does not mean side effects are trivial. Nausea can limit dose escalation, reduce adherence, and make a therapy that works in a trial difficult to continue in ordinary life.

Families and clinicians should discuss tolerability before treatment begins, including what symptoms merit a dose adjustment or reassessment. A prescription is the start of monitoring, not the end of decision-making.

What adult evidence can—and cannot—tell us

Adult studies make the pediatric findings biologically plausible, but they do not fill pediatric evidence gaps. In adults with type 2 diabetes, a meta-analysis of cardiovascular outcomes trials by Tsapas et al. found GLP-1 receptor agonists reduced major adverse cardiovascular events by 13% (hazard ratio 0.87). Those trials involved 43,456 adults and measured outcomes that are too rare in adolescent trials to use as practical endpoints.

Likewise, a 2025 network meta-analysis by Gao et al. compared GLP-1 drugs, SGLT2 inhibitors, and sulfonylureas in adults with type 2 diabetes and heart failure. Its cardiovascular and renal findings describe adult disease management, not the expected long-term outcome of starting a GLP-1 drug at age 12 or 16.

Liver data require the same restraint. A 2025 meta-analysis by Li et al. found that GLP-1 and dual agonist therapies improved histologic outcomes in adults with metabolic dysfunction-associated steatohepatitis. The analysis included six studies and 1,726 adults; compared with placebo, treatment increased the odds of histologic improvement without worsening fibrosis (odds ratio 4.51, 95% confidence interval 3.68 to 5.52). No pediatric MASH randomized trial data establish the same outcome in adolescents.

A smaller, real-world signal in type 1 diabetes

A 2026 retrospective cohort study by Gonzalez et al. examined adolescents and young adults aged 10 to 20 with type 1 diabetes and obesity who received GLP-1 drugs in clinical care. The study reported reductions in BMI and total daily insulin dose among 24 patients.

This is a clinically distinct group, and the study was observational rather than randomized. It can describe an association, not prove that GLP-1 treatment caused every observed change. Changes in insulin management, diet, activity, clinical follow-up, and regression to the mean can all influence results without a control group. The finding is useful context, not confirmation of the randomized-trial effect.

The unanswered questions are the long-term ones

The main limitation is not that pediatric trials point in opposite directions. They generally favored GLP-1 treatment over placebo. The problem is precision and duration: five small trials cannot reliably answer which drug, dose, or patient subgroup performs best, and high heterogeneity makes a single pooled number less portable than it looks.

No published pediatric evidence in this review establishes the trajectory of weight after GLP-1 treatment stops. Adult discontinuation data raise concern about rebound, but pediatric rebound has not been measured well enough to quantify. That matters because obesity usually requires ongoing management; a teenager who starts medication may face a decision about long-term treatment before long-term pediatric outcomes exist.

Long-term pediatric data are also lacking for bone mineral density during growth, pubertal timing and progression, gallbladder disease, and thyroid C-cell tumor risk. The thyroid warning comes from rodent findings, not established pediatric human harm. It remains a class-level safety concern that short pediatric trials cannot settle.

GLP-1 drugs have demonstrated short-term efficacy for adolescents with obesity. They have not yet demonstrated decades of safety, durable benefit after discontinuation, or prevention of adult cardiovascular disease when started in adolescence.

The practical verdict

For adolescents who meet approved indications, GLP-1 receptor agonists are evidence-based options under pediatric obesity care. The randomized evidence supports lower BMI, body weight, waist circumference, HbA1c, and systolic blood pressure versus placebo, while STEP TEENS adds evidence of improved insulin sensitivity and cardiometabolic risk factors with semaglutide.

The decision deserves the same seriousness as the condition. A clinician experienced in pediatric obesity management should weigh expected benefit, gastrointestinal tolerability, mental and physical development, family capacity for follow-up, and the possibility that treatment could extend for years. The drugs work within the studied timeframe. What happens across adolescence and after stopping treatment remains unanswered.